2025
Global estimates of rotavirus vaccine efficacy and effectiveness: a rapid review and meta-regression analysis
Prunas O, Asare E, Sajewski E, Li Y, Pithawala Z, Weinberger D, Warren J, Armah G, Cunliffe N, Iturriza-Gómara M, Lopman B, Pitzer V. Global estimates of rotavirus vaccine efficacy and effectiveness: a rapid review and meta-regression analysis. EClinicalMedicine 2025, 81: 103122. PMID: 40115174, PMCID: PMC11925534, DOI: 10.1016/j.eclinm.2025.103122.Peer-Reviewed Original ResearchRotavirus-associated gastroenteritisRotavirus vaccine efficacyPredicting vaccine efficacyVaccine efficacyVaccine effectivenessVaccine performanceNational rotavirus immunization programImpact of rotavirus vaccinationRotavirus immunization programAffecting young childrenBill &Meta-regression analysisRandomized Controlled TrialsSystematic review of studiesEstimates of vaccine effectivenessRotavirus morbidityMelinda Gates FoundationRotavirus vaccineCohort studyLicensed vaccinesVaccine trialsDecreased efficacyControlled TrialsCase-controlLow-income settings
2024
Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020–30: a modelling study
Hartner A, Li X, Echeverria-Londono S, Roth J, Abbas K, Auzenbergs M, de Villiers M, Ferrari M, Fraser K, Fu H, Hallett T, Hinsley W, Jit M, Karachaliou A, Moore S, Nayagam S, Papadopoulos T, Perkins T, Portnoy A, Minh Q, Vynnycky E, Winter A, Burrows H, Chen C, Clapham H, Deshpande A, Hauryski S, Huber J, Jean K, Kim C, Kim J, Koh J, Lopman B, Pitzer V, Tam Y, Lambach P, Sim S, Woodruff K, Ferguson N, Trotter C, Gaythorpe K. Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020–30: a modelling study. The Lancet Global Health 2024, 12: e563-e571. PMID: 38485425, PMCID: PMC10951961, DOI: 10.1016/s2214-109x(23)00603-4.Peer-Reviewed Original ResearchConceptsCatch-up activitiesVaccine-preventable disease burdenCatch-upVaccine Impact Modelling ConsortiumImmunisation servicesMiddle-income countriesEffectiveness of HPV vaccinationVaccine effectivenessAffected cohortBill & Melinda Gates FoundationImmunisation coverageLow-incomeLong-term effectsWHO-UNICEFDisease burdenVaccination coverageCalendar yearImmunisation effortsMelinda Gates FoundationMitigation measuresCountriesYears of vaccinationYellow fever vaccine
2023
Assessment of vaccine herd protection in a cluster-randomised trial of Vi conjugate vaccine against typhoid fever: results of further analysis
Khanam F, Kim D, Liu X, Voysey M, Pitzer V, Zaman K, Pollard A, Qadri F, Clemens J. Assessment of vaccine herd protection in a cluster-randomised trial of Vi conjugate vaccine against typhoid fever: results of further analysis. EClinicalMedicine 2023, 58: 101925. PMID: 37090439, PMCID: PMC10114505, DOI: 10.1016/j.eclinm.2023.101925.Peer-Reviewed Original ResearchVaccine herd protectionCluster-randomised trialHerd protectionTransmission of typhoidVi-TTTyphoid feverChildren 9 monthsVi-tetanus toxoidMonths of followJapanese encephalitis vaccineYears of ageTotal vaccine effectivenessUrban Bangladeshi childrenVaccine effectivenessEncephalitis vaccineStudy populationBangladeshi childrenTreatment centersCluster residentsIndirect effectivenessMelinda Gates FoundationTrialsVaccineAnalysis of subpopulationsFever
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply